Vaccinations have begun in a phase I human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate. Nikki Withers speaks to Dr Daniel Hoft and Christopher Fox about the formulation process and what this means for vaccine development going forward.

Tuberculosis (TB) is one of the leading infectious causes of death worldwide, infecting around one third of the world’s population, says Dr Daniel Hoft, director of the Division of Infectious Diseases, Allergy and Immunology at the Saint Louis University School of Medicine, who is involved in developing a novel, freeze-dried vaccine to help fight the disease. "We are testing a state-of-the-art vaccine, which targets multiple vulnerable points in the TB bacterium’s lifecycle," he says. "The vaccine does not require a cold chain, which is critically important."

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.